Comparison between Chondrogenic Markers of Differentiated Chondrocytes from Adipose Derived Stem Cells and Articular Chondrocytes In Vitro

Mohmmad Mardani1, Batool Hashemibeni1, Malek Masoud Ansar1, Sayeed Hamid Zarkesh Esfahani2, Mohmmad Kazemi1, Vahid Goharian3, Nafiseh Esmaeili4, Ebrahim Esfandiary*1

1 Department of Anatomical Sciences and Molecular Biology, Medical School, Esfahan University of Medical Sciences, Esfahan, Islamic Republic of Iran
2 Department of Immunology, Medical School, Esfahan University of Medical Sciences, Esfahan, Iran
3 Annn Hospital, Medical School, Esfahan University of Medical Sciences, Esfahan, Esfahan, Islamic Republic of Iran
4 Department of Immunology; Medical School, Esfahan University of Medical Sciences, Esfahan, Islamic Republic of Iran

ABSTRACT

Objective(s): Osteoarthritis is one of the most common diseases in middle-aged population in the world. Cartilage tissue engineering (TE) has been presented as an effort to introduce the best combination of cells, biomaterial scaffolds and stimulating growth factors to produce a cartilage tissue similar to the natural articular cartilage. In this study, the chondrogenic potential of adipose derived stem cells (ADSCs) was compared with natural articular chondrocytes cultured in alginate scaffold.

Materials and Methods: Human ADSCs were obtained from subcutaneous adipose tissue and human articular chondrocytes from non weight bearing areas of knee joints. Cells were seeded in 1.5% alginate and cultured in chondrogenic media for three weeks with and without TGFβ3. The genes expression of types II and X collagens was assessed by Real Time PCR and the amount of aggrecan (AGC) and type I collagen measured by ELISA and the content of glycosaminoglycan evaluated by GAG assay.

Results: Our findings showed that type II collagen, GAG and AGC were expressed, in differentiated ADSCs. Meanwhile, they produced a lesser amount of types II and X collagens but more AGC, GAG and type I collagen in comparison with natural chondrocytes (NCs).

Conclusion: Further attempt should be carried out to optimize achieving type II collagen in DCs, as much as, natural articular chondrocytes and decline of the production of type I collagen in order to provide efficient hyaline cartilage after chondrogenic induction, prior to the usage of harvested tissues in clinical trials.

Please cite this paper as:
Mardani M, Hashemibeni B, Ansar MM, Zarkesh Esfahani SH, Kazemi M, Goharian V, Esmaeili N, Esfandiary E. Comparison between Chondrogenic Markers of Differentiated Chondrocytes from Adipose Derived Stem Cells and Articular Chondrocytes In Vitro. Iran J Basic Med Sci; 2013; 16:763-771.

Introduction

Based on the current statistics, millions of people in the world suffer from articular diseases which are associated with joint destruction (1-3). Traditional treatments, despite some successes, have not yet been satisfactory (4, 5). Thus tissue engineering which is a combination of engineering principles and biological sciences has been considered to have an important role in the treatment of articular lesions (6). Tissue engineering is seeking for cellular biomaterial scaffolds and appropriate stimulating growth factors to produce alternative hyaline articular cartilage that could be transplanted in order to treat articular defects (7-10).

The selection of suitable cells is often difficult, as cells should be autologous (not responsive immunologically), having high proliferative power and potentially differentiable to the desired target cells (11). Autologous chondrocytes are the first differentiated cells used for cartilage tissue engineering, then neonatal (12) and finally fetal (13) chondrocytes. Due to some limitations of using mentioned cells, adult undifferentiated stem cells with high differentiation ability to chondrocytes, have been considered as an alternative. Among different sources of stem cells, those of adipose derived stem cells (ADSCs) and bone marrow derived mesenchymal stem cells (BM-MSCs) have been used in cartilage tissue engineering (15-17). In recent years due to ease of accessibility to...
subcutaneous adipose tissue and availability of large quantity of cells compared with the bone marrow, ADSCs have received a great interest (18-20). So far, the characteristics of ADSCs have not been well defined and more investigation is necessary (20, 21).

Another important factor in TE is selection of proper biomaterial scaffold which should have biocompatibility, biodegradability and facilitator of tissue proliferation and proper biomechanical properties (23, 24). In TE both hydrogels and porous scaffolds are used. Alginate is a kind of natural hydrogel which is derived from seaweed. Many researchers have investigated this hydrogel as an injectable seeded chondrocytes scaffold for articular cartilage repairmen (25-27). Previous studies have indicated that differentiated chondrocytes from ADSCs in alginate were morphologically spherical and similar to natural chondrocytes. Moreover, differentiation trend requires other suitable growth factors as well as scaffolds such as TGFβ, FGF, IGF and BMP (1). Among these, TGFβs including TGFβ1, TGFβ2, TGFβ3 and BMPs have the most potential for differentiation induction to chondrocytes in MSCs. It is reported that TGFβ2, TGFβ3 are more effective in induction of human MSCs to chondrocytes than TGFβ3 (30). In the past two decades except few cases no suitable cartilage tissue has been designed in vitro for clinical applications (14, 31). Therefore, it seems that TE is still at its infancy and in order to address many clinical issues, a long way should be followed. It is hoped that, by clarifying ambiguities such as, precise mechanisms of differentiation of stem cells to the chondrocytes, the pattern of interaction with various scaffolds, further determination of differences between articular chondrocytes. Moreover, the differentiated chondrocytes from stem cells, a functional long life engineered cartilage tissue similar to articular cartilage would be presented to the medical fields (1, 29).

Many scientists have compared chondrogenesis between articular chondrocytes and chondrocytes derived from stem cells. Gleghorn et al (2005) and Mauck et al (2006) announced that mechanical properties and matrix extent produced by BM-MSCs derived chondrocytes in alginate is lower than the articular ones (32, 33). Jakobsen et al (2009) stated that type II collagen in BM-MSCs and ADSCs was equal to the natural chondrocytes in hyaluronic acid scaffold (34). In addition, Tigli et al (2009) revealed that the expression of chondrogenic markers, in embryonic stem cells, BM-MSCs, ADSCs and MSCs derived from embryonic stem cells improved in silk and chitosan than articular chondrocytes (35). Mahmoudifar et al (2010) indicated the higher chondrogenic potential in fetal chondrocytes compared with ADSCs in polyglycolic acid (PGA) (13). Despite such investigation on differentiation of ADSCs to chondrocytes and articular chondrocytes in alginate, no reported comparison between these cells has been made. Therefore, we aimed to assess and compare types II, X, I collagens, aggrecan and glycosaminoglycan (GAG) of differentiated chondrocytes from ADSCs, with natural articular chondrocytes seeded in alginate with and without TGFβ3 on days 14 and 21.

Materials and Methods

Isolation and proliferation of ADSCs

Written consent was obtained from all patients in an operation room. Subcutaneous adipose tissue (~10 g) was obtained from 4 patients (30-50 years age), under sterile conditions and transferred to the lab. Afterward, it was digested with 0.075% collagenase type I (Sigma) at 37°C for 30 min. The enzyme was inactivated by DMEM LG (Sigma) containing 10% FBS (Invitrogen). Subsequently, the resultant solution was centrifuged (1200 rpm, 15 min) and cell pellet was cultured in 25 cm² flasks with DMEM LG, 10% FBS, 1% penicillin & streptomycin (Gibco) and incubated with 5% CO₂, 37°C. The medium was changed every 4 days. Cells were detached with 0.05% trypsin/0.53 mM EDTA (Sigma) and passaged, when they reached 80% confluence. P3-p5 cells were seeded in an alginate scaffold.

Isolation and proliferation of articular chondrocytes

After taking a written consent, a bit of articular cartilage was obtained by the knee arthroscopy from 4 patients (20-30 years age) whose joints did not show any signs of a degenerative arthritis. The specimens were taken from non-weight bearing areas and transferred within PBS (Sigma) to the lab. The specimens were then divided into 1×1 mm slices and digested with collagenase type II (Sigma) 350 u/ml in 37°C for 4 hr. After inactivation with DMEM F12 (Gibco) with 10% FBS, the solution was centrifuged and cell pellets were cultured in 25 cm² flask with DMEM F12, 10% FBS, 1% penicillin and streptomycin. When cells reached 80% confluence, they were detached with trypsin/EDTA and passaged. P2-P4 cells were used for seeding in an alginate scaffold.

Encapsulation and culture procedure in alginate

Initially, ADSCs (P3-P5) and articular chondrocytes (p2-p4) were separately resuspended in 1.5% alginate (Sigma) at 5×10⁶ cells/ml. The alginate/cell suspension was expressed through a 23-gauge needle into a 102 mM CaCl₂ solution (Merck). The alginate beads after 15 min were washed twice in 0.9% saline solution and once in DMEM-HG (Gibco), and finally 2 ml chondrogenic media was added to each well of 12-well. Chondrogenic culture media contained: DMEM-HG (High Glucose)Gibco), penicillin & streptomycin 1% (Gibco), dexamethasone 10⁻⁷M (Sigma), ascorbat-2-phosphate 50 µg/ml (Sigma), bovine serum albumin 1% (Sigma), linoleic acid 5µg/ml (Sigma), insulin-
transferrin-selenium (ITS) 1% (Sigma), with and without adding transforming growth factor-β3 (TGFβ3) 10 ng/ml (Sigma).

The plates were incubated with 5% CO2 at 37° and replaced every 4 days. Supernatant mediums on days 14 and 21 were frozen at -20° for ELISA.

ELISA
AGC and type I collagen produced in supernatant media with and without TGFβ3 on days 14 and 21 was measured by ELISA. For AGC the kit was from Invitrogen (Cat No KAP1461) and type I collagen was from MD bioproducts (Cat No M036007) according to their manufacturers’ protocols. Finally, samples were read in ELISA reader (Hyperion, Microread 4 plus) with 450 nm wavelength.

Biochemical assays
DNA quantification
In order to determine DNA and GAG, first, alginate beads on days 14 and 21 digested for 18 h at 60°C in papain solution 125µg/ml (Sigma) containing cysteine10 mM (Sigma) in PB (pH=6.5). For each 12 beads, one ml enzyme was used. The resultant solutions were used for determination of DNA and GAG.

The content of DNA (ng/ml) was measured using DNA Quantification Kit, Fluorescence Assay (Sigma, Cat. No. DNAQF), according to its manufacturer’s protocol. Briefly, resultant solution was read by dry Edhoest 33258 and absorbance of each sample was read by spectrophotometer (Perkin Elmer LS-3) at 360 nm in excitation and 460 nm wavelength in emission. Afterward, the DNA content was calculated according to the thymic calf standard curve.

GAG Assay
The amount of GAG (µg/ml) was quantified using 1, 9-dimethylmethylene blue (DMMB) dye. Briefly, 100µl of resultant solution was mixed with 2400 µl of DMB solution in a cuvette and then its absorbance in 525 nm wavelength was read by spectrophotometer (Spectronic 70, Baucsh& lomb). The GAG content was calculated using standard curve chondroitin sulfate of bovine trachea.

The GAG content was calculated using standard curve chondroitin sulfate of bovine trachea. The amount of GAG (µg/ml) was quantified using dimethylmethylene blue (DMMB) dye. Briefly, 100μl of resultant solution was mixed with 2400 μl of DMMB dye and absorbance of each sample was read by spectrophotometer (Spectronic 70, Baucsh&lomb). The GAG content was calculated using standard curve chondroitin sulfate of bovine trachea.

Results
Gene expression of type II and X collagens
The results of Real-Time PCR indicated that type II collagen gene expression in articular chondrocytes (NGs) is significantly higher ($P<0.001$) than differentiated chondrocytes (DCs) after two weeks.

Table 1. Primers used in Real Time PCR

| Gene   | Primer sequences                  | Size (Base pair) |
|--------|-----------------------------------|------------------|
| colagenII-F | CGTGGATGATGGTGAAG               | 130              |
| colagenII-R | CCTGGATACCTGTGAAG               | 130              |
| colagen x-F | AAGATCCATCTTCCAGAATG            | 187              |
| colagen x-R | CCTTATGCTCATACCTTCA             | 187              |
| GAPDH-F  | AGGCTCATTTCCGGTAT          | 125              |
| GAPDH-R  | CCTGTCCTTTGCTCGT              | 125              |

Statistical tests
Kolmogorov-Simonov test was used for assessing the normal distribution of variables. ANOVA (one-way-analysis of variance) with LSD post hoc test was used for comparison of ELISA, Real-Time PCR and GAG assay results in different groups.

Table 1. Primers used in Real Time PCR

Gene Primer sequences Size (Base pair)

colagenII-F CGTGGATGATGGTGAAG 130
colagenII-R CCT GGATACCTGTGAAG 130
colagen x-F AAGATCCATCTTCCAGAATG 187
colagen x-R CCTTATGCTCATACCTTCA 187
GAPDH-F AGGCTCATTTCCGGTAT 125
GAPDH-R CCTGTCCTTTGCTCGT 125
Table 2. Results of chondrogenic markers in differentiated chondrocytes (DCs) and articular chondrocytes (NCs) on days 14 and 21

| Groups     | Collagen II (RQ) | Collagen X (RQ) | Collagen I μg/ml | Aggrecan ng/ml | GAG/DNA μg/ng |
|------------|-----------------|-----------------|------------------|----------------|---------------|
| +DCs(14)   | 18.34           | 126.26*         | 0.316            | 286.533*       | 0.35*         |
| -DCs(14)   | 1.275           | 5.415           | 0.575            | 19.06333       | 0.095         |
| +NCs(14)   | 195.16**        | 0.0013          | 0.27             | 14.5           | 0.3           |
| -NCs(14)   | 457.4505*       | 0.0003          | 0.2102           | 15.03333       | 0.24          |
| +DCs(21)   | 34.19           | 0.1759          | 1.0612*          | 13.46667       | 0.55**        |
| -DCs(21)   | 4.03            | 2.73            | 0.5167           | 19**           | 0.19          |
| +NCs(21)   | 3.675           | 75.09**         | 0.6697*          | 16.26667       | 0.24          |
| -NCs(21)   | 13.465          | 87.35           | 0.2425           | 14.1           | 0.21          |

Collagen II: *P<0.001 vs. other groups on day 14. **P<0.001 vs. DCs groups on day 14. Collagen X: *P<0.001 vs. DCs groups on day 14. Collagen I: *P<0.001 vs. all other groups on day 14 & 21. Aggrecan: *P<0.001 vs. all other groups on days 14 & 21. GAG: *P<0.001 vs. all other groups on days 14 & 21.

TGFβ3 resulted in a significant (P<0.001) decrease of type II collagen expression in NCs, but its expression reduced strongly in both groups of NCs at the end of third week. Also, TGFβ3 caused increase in type II collagen gene expression in DCs in third week than in second week. Nevertheless, DCs expressed the lowest amount of type II collagen in second and third weeks. (Figure 1, A) (Table 2).

The highest amount of type X collagen gene expression, a hypertrophic factor, was seen in articular chondrocytes (NCs) in third week while it was significantly (P<0.05) more than differentiated chondrocytes (DCs), but it was not expressed in these cells in the second week. Adding TGFβ3 led to significant increase of gene expression in third week (P<0.001) compared to NCs without TGFβ3. Also, DCs in the presence of this growth factor significantly (P<0.05) expressed type X collagen higher than other group without it at the end of second week. Generally, with the course of time and in third week DCs no longer expressed this gene (Figure 1, B) (Table 2).
Differentiated and Native Chondrocytes in Alginate

Mardani M et al

Iran J Basic Med Sci, Vol. 16, No. 6, Jun 2013

767

Figure 2. The results of ELISA analysis for collagen type I and aggrecan in supernatant media of DCs and NCs with and without TGFβ3 on days 14 & 21. Values are the means ±SE of triplicate experiments. (A) *P<0.05 vs. all other groups on day14&21. **P<0.05 vs. –NCs on day 21 and NCs groups on day 14. (B) *P<0.001 vs. all other groups on days 14 &21. **P<0.001 vs. all other groups on day 14&21(lower concentration than +DCs on day 14 and higher one than other groups). No significant difference was shown in aggrecan content of –DCs groups on days 14&21.+DCs, Differentiated chondrocytes with TGFβ3; -DCs, Differentiated chondrocytes without TGFβ3; +NCs, natural articular chondrocytes with TGFβ3; -NCs, natural articular chondrocytes without TGFβ3.

Figure 3. The GAG content in DCs and NCs with and without TGFβ3 on days 14 & 21. Values are the means ±SE of duplicate experiments.* P<0.001 vs. -DCs and NCs groups on day 14. ** P<0.001 vs. all other groups on days 14 &21. +DCs, Differentiated chondrocytes with TGFβ3; -DCs, Differentiated chondrocytes without TGFβ3; +NCs, natural articular chondrocytes with TGFβ3; -NCs, natural articular chondrocytes without TGFβ3.
Production of Aggrecan, Type I collagen and GAG

The results of ELISA indicated that articular chondrocytes (NCs) produced aggrecan (AGC) constantly during second and third weeks and TGFβ3 had no effect on it. In general, differentiated chondrocytes (DCs) generated more AGC than NCs which was significantly different (P<0.001) in second week. In the presence of TGFβ3, DCs caused more significant production in second week but decreased in third week compared to other group without TGFβ3 (P<0.001). (Figure 2, B) (Table 2).

In general, type I collagen production increased in all groups in third week in comparison to second week. However, articular chondrocytes (NCs) produced less type I collagen in two time points which showed significant difference (P<0.05) only in third week. Adding TGFβ3 to DCs and NCs yielded more type I collagen in third week indicating significant difference (P<0.05) compared to NCs and DCs without TGFβ3. (Figure 2, A) (Table 2).

The results of GAG assay indicated that in third week articular chondrocytes (NCs) produced glycosaminoglycan (GAG) less than second week but the trend of its production in differentiated chondrocytes (DCs) was significantly increased in third week compared to second week (P<0.001). In addition, TGFβ3 resulted in significant increase in GAG production than other groups without it in NCs and DCs in two time points in that the highest amount was related to DCs (P<0.001). Generally, DCs generated more GAG than NCs in second and third weeks (Figure 3) (Table 2).

Discussion

One of the aims of TE is to find a suitable alternative cell source to synthesize an extracellular matrix similar to natural cartilage (35). In recent years, several researchers have studied chondrogenesis in ADSCs and have compared them with other cells in different scaffolds and various growth factors (17-20, 32,35) but there is no detailed comparison between differentiated cells from ADSCs and natural articular chondrocytes in alginate. In this study, we compared differentiated chondrocytes from ADSCs and articular chondrocytes separately in alginate with and without TGFβ3 for 21 days.

According to our findings, the gene expression of type II collagen, GAG production and their progressive increase during 21 days. In addition, the existence of aggrecan (AGC) in supernatant media as essential cartilage markers in differentiated chondrocytes (DCs), confirms that ADSCs have been differentiated to chondrocytes. Comparing results of these markers between DCs and articular chondrocytes (NCs) after two weeks, indicated that gene expression of type II collagen was significantly lower than NCs, which was in consistent with previous reports about BM-MSCs in agarose and ADSCs in polyglycolic acid (PGA)(33, 13). However, it was reported that in hyaluronic acid scaffold type II collagen expressed equally by ADSCs or chondrocytes and BM-MSCs expressed more than chondrocytes and the effect of BMP2 as well as TGFβ1 may have a role in this phenomenon. Unlike previous studies, our results indicated that DCs produced more AGC and GAG than NCs (33, 32).

Tigli et al (2009) indicated that embryonic stem cells (ESCs), ESCs derived MSCs, ADSCs and BM-MSCs in silk and chitosan, expressed chondrogenic markers, such as type II collagen, Sox9 and AGC more than NCs (35) which is consistent with our findings about GAG and AGC but in contrast to type II collagen. This discrepancy may be due to the application of two growth factors, BMP2 and TGFβ1 at the same time and interaction between these factors and two other different scaffolds. Increasing level of GAG production in DCs and superiority to NCs and also gene expression of type II collagen and generation of AGC in third week indicates that DCs in alginate during three weeks will maintain its phenotype. Decrease of some chondrogenic markers in third compared to second week such as AGC in DCs or type II collagen and GAG production in NCs may be due to the fact that the highest amount of extracellular matrix was released on day 14 and therefore the matrix molecules themselves caused reduction of these markers as a negative feedback and modification of chondrocyte metabolism (37, 38). On the other hand, gene expression of type X collagen—a hypertrophic factor in embryonic stage- (39) was considered as a big challenge during differentiation of BM-MSCs and ADSCs to chondrocytes (30, 40, 41) and chondrocytes redifferentiation in various scaffolds and pellet culture (35, 42, 43). In this study, type X collagen in DCs was expressed significantly more than NCs after two weeks, but reduced considerably and distinguished after three weeks. Its concomitant with type II collagen gene expression and GAG production increase and continuation of AGC production at this point are positive signals for differentiation.

Of course the gene expression of type X collagen is not necessarily accompanied with collagen X protein production and hypertrophy (44) which may be the sign of rapid maturation of these cells (42). Some studies have reported that, healthy adult chondrocytes in tissue engineering have not or very little- expressed this gene (45-47). Other studies stated that, articular chondrocytes expressed less type X collagen, compared to ESCs-derived MSCs in silk and chitosan (35), ADSCs in hyaluronic acid (34) and pellet culture (48), which was in contrast with our present findings in the third week. However, in line with our results, it was reported gene expression of type X collagen by BM-MSCs in silk and chitosan was lower than articular chondrocytes (35).
Types I and X collagens are considered as negative markers in chondrogenesis. It has been noted that MSCs especially ADSCs and BM-MSCs produce a lot of collagen type I (20, 49, 50). For TE, the expression of this gene is not appropriate and after in vitro implantation produces fibrocartilage instead of hyaline (13). Principally, scaffolds that maintain spherical shape of cells and prevent their contact to each other like agarose and alginate-enhance chondrogenesis and inhibit production of collagen type I (22). Progressive increase of type I collagen production in all groups of our study during three weeks means that other factors may be involved other than scaffold and TGFβ3 in vitro. This gradual increase of type I collagen is in line with the report of Jakobsen et al (34) but in contrast with Yang et al (51). In consistent with our findings, it was reported that type I collagen in MSCs pellets culture, silk and chitosan scaffolds were produced more than NCs (35, 48). Conversely, it was reported that type I collagen in ADSCs and BM-MSCs in hyaluronic acid was equal to NCs (34).

The detection of AGC and type I collagen proteins in supernatant media by ELISA is due to lack of adequate structural consistency around the cells and washing away into the supernatant media. In a similar study, Jacobsen et al noted that despite high gene expression of type II collagen by BM-MSCs encapsulated in hyaluronic, immunohistochernistry technique did not show a large quantity of type II collagen in resultant tissue, while it was detectable in supernatant media by ELISA (34).

Transforming growth factor type beta (TGFβ) is the frequently used growth factor for chondrogenesis in vitro which has a major role in initiation of chondrogenesis. A lot of studies indicated its provoking role in proliferation and generation of cartilage matrix in progenitor cells (52-54). The review of literature denoted that TGFβ has different effects in chondrogenesis. Other studies have mentioned that type II collagen and GAG production were stimulated by TGFβ (55) and still some other groups have reported that it inhibits collagen and GAG production chondrocytes (56). TGFβ1 has a contribution in early stages (57) and TGFβ3 in chondrocyte maturation (58). It was reported that TGFβ3 increases gene expression of type II collagen in MSCs encapsulated in alginate (59), but Estes et al reported that TGFβ1 and TGFβ3 has no difference in proliferation, gene expression and cartilage biosynthetic activity in ADSCs in alginate (20). Moreover, the improvement of synthesis of chondrogenic markers such as AGC, link proteins, fibromodulin and decorin in MSCs and pellet culture in the presence of TGFβ3 has been clarified (16, 30). We found TGFβ3 improves chondrogenic markers such as AGC, GAG and type II collagen in DCs, which is alignment with some other previous reports (33, 55). However, it inhibits or has limited benefits in NCs which is in line with findings of Skantze et al (56) and in contrast with report of Mauck et al (33). Moreover, this growth factor has no effect in reducing of negative chondrogenic markers, types X and I collagens which is more prominent in third week. It was believed, TGFβ as a chondrogenic factor in vitro, causes retention of differentiated chondrocytes from MSCs in prehypertrophic state (60).Williams et al reported that TGFβ1 in MSCs, improved chondrogenic markers and inhibited collagen I (61), but Mahmoudifar et al stated that it had limited effect in cartilage synthesis (13).

Conclusion

ADSCs are multipotential cells easily obtainable from subcutaneous adipose tissue and so can be used as an alternative cell source for cartilage TE. According to our findings, despite low gene expression of type II collagen as a main chondrogenic marker, the trend gradually increased progressively from day 14 to 21. One reason is that more time may be required for ADSCs maturation after differentiation to chondrocytes compared to the natural articular chondrocytes (33). Type X collagen which is considered as a hypertrophic factor decreased during 21 days and possessed appropriate condition in DCs. However, type I collagen synthesis had a progressive trend that may lead to fibrocartilage instead of hyaline cartilage which is not suitable. It seems that more studies should be carried out to find new ways to produce type II collagen as much as possible and to inhibit type I collagen during chondrogenic differentiation of MSCs in various scaffolds in order to have efficient articular cartilage in vitro to be used in clinics.

Acknowledgment

Special thanks go to IRAN National Science Fund for financial supporting of the project No.90000737. We also appreciate Mr. R. Haghiri and Dr M. Moien Ansar for their sincere help that without their contribution this study could not be performed.

References

1. Csaki C, Matis U, Mobasher A, Ye H, Shalihaei M. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. Histochem Cell Biol 2007; 128: 507-520.
2. Buckwalter JA, Manlin HJ. Articular cartilage: degeneration and osteoarthritis, repair, regeneration and transplantation. Instr Course Lect 1998; 47:487-504.
3. Mano JF, Reis RL. Osteochondral defects: present situation and tissue engineering approaches. J Tissue Eng Regen Med 2007; 1: 261-273.
4. Hunziker EB. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 2002; 10: 432-463.
5. Browne JE, Branch TP. Surgical alternatives for treatment of articular cartilage lesions. J Am Acad Orthop Surg 2000; 8:180-189.
6. Langer R, Vacanti JP. Tissue engineering. Science 1993; 260: 920-926.
7. Guilak F, Butler DL, Goldstein SA. Functional tissue engineering: the role of biomechanics in articular cartilage repair. Clin Orthop Relat Res 2001; 391: 295-305.
8. Song L, Balsh D, Tuan RS. Mesenchymal stem cell-based cartilage tissue engineering: cells, scaffold and biology. Cytotherapy 2004; 6: 596-601.
9. Chaikof EL, Matthew H, Kohn J, Mikos AG, Prestwich GD, Yip CM. Biomaterials and scaffolds in reparative medicine. Ann N Y Acad Sci 2002; 961:96–105.
10. Naughton GK. From lab bench to market: critical issues in tissue engineering. Ann N Y Acad Sci 2002; 961:372–385.
11. Hilliker A, Kasper C, Hass R, Haverich A. Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? Langenbecks Arch Surg 2011; 396: 489-497.
12. Adkisson HD 4th, Martin JA, Amendola RL, Milliman C, Mauch KA, Katwal AB, et al. The potential of human allogeneic juvenile chondrocytes for restoration of articular cartilage. Am J Sports Med 2010; 38: 1324-1333.
13. Mahmoudifar N, Doran PM. Extent of cell differentiation and capacity for cartilage synthesis in human adult adipose-derived stem cells: comparison with fetal chondrocytes. Biotechnol Bioeng 2010; 107:393-401.
14. Keeney M, Lai JH, Yang F. Recent progress in adult stem cells from bone marrow: differentiation - dependent gene expression of matrix components. Exp Cell Res 2011; 200:109-200.
15. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation of human adipose-derived stem cells in pellet culture system. Iran J Basic Med Sci 2008; 11:10-17.
16. Hashemi beni B, Razavi S, Esfandari E, Karbasi S, Mardani M, Nasrsefahani M. Induction of chondrogenic differentiation of human adipose-derived stem cells with TGF-ß3 in pellet culture system. Iran J Basic Med Sci 2008; 11:10-17.
17. Erickson GR, Guilak JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 290: 763-769.
18. Rowley JA, Madlambayan G, Mooney DJ. Alginic hydrogels as synthetic extracellular matrix materials. Biomaterials 1999; 20:45–53.
19. Mauch RL, Yuan X, Tuan RS. Chondrogenic differentiation and functional maturation of bovine mesenchymal stem cells in long-term agarose culture. Osteoarthritis Cartilage 2006; 14: 179-189.
20. Wang Y, Kim UJ, Blasioli DJ, Kim HJ, Kaplan DL. In vitro characterization, and differentiation potential. Cytotherapy 2003; 5:362-369.
21. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6. Arthritis Rheum 2006; 54: 1222–1232.
22. Erickson GR, Guilak JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic Potential of Adipose Tissue-Derived Stromal Cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 290: 763-769.
23. Mauch RL, Yuan X, Tuan RS. Chondrogenic differentiation and functional maturation of bovine mesenchymal stem cells in long-term agarose culture. Osteoarthritis Cartilage 2006; 14: 179-189.
24. Awad HA, Wielch MQ, Leddy HA, Guilak F. Chondrogenic differentiation of adipose-derived adult stem cells in agarose, alginic, and gelatin scaffolds. Biomaterials 2004; 25: 3221–3228.
25. Pircher H, Awad HA, Guilak F. Molecular diffusion in tissue-engineered cartilage constructs: effects of scaffold material, size, and culture conditions. J Biomed Mater Res B Appl Biomater 2004; 70: 397–406.
26. Barry F, Boynton RE, Liu B, Murphy JM. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation - dependent gene expression of matrix components. Exp Cell Res 2011; 200:109-200.
27. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation of human adipose-derived stem cells in pellet culture system. Iran J Basic Med Sci 2008; 11:10-17.
28. Hashemi beni B, Razavi S, Esfandari E, Karbasi S, Mardani M, Nasrsefahani M. Induction of chondrogenic differentiation of human adipose-derived stem cells with TGF-ß3 in pellet culture system. Iran J Basic Med Sci 2008; 11:10-17.
29. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6. Arthritis Rheum 2006; 54: 1222–1232.
30. Erickson GR, Guilak JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic Potential of Adipose Tissue-Derived Stromal Cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 290: 763-769.
31. Mauch RL, Yuan X, Tuan RS. Chondrogenic differentiation and functional maturation of bovine mesenchymal stem cells in long-term agarose culture. Osteoarthritis Cartilage 2006; 14: 179-189.
32. Jakobsen RB, Shahadadfar A, Reinhold FP, Brinchmann JE. Chondrogenesis in a hyaluronic acid scaffold: comparison between chondrocytes and MSC from bone marrow and adipose tissue. Knee Surg Sports Traumatol Arthrosc 2010; 18:1407–1416.
33. Seda Tigli RS, Ghosh S, Laha MM, Shevy ND, Daheron L, Guillem J, et al. Comparative chondrogenesis of human cell sources in 3D scaffolds. J Tissue Eng Regen Med 2009; 3:348-360.
34. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6. Arthritis Rheum 2006; 54: 1222–1232.
35. Erickson GR, Guilak JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic Potential of Adipose Tissue-Derived Stromal Cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 290: 763-769.
36. Aguir DJ, Knudson W, Knudson CB. Internalization of the hyaluronan receptor CD44 by chondrocytes. Exp Cell Res 1999; 252: 292–302.
37. Shn G. The role of type X collagen in facilitating and regulating endochondral ossification of articular cartilage. Orthod Craniofac Res 2005; 8: 11-17.
38. Wang Y, Kim UJ, Blasioli DJ, Kim HJ, Kaplan DL. In vitro characterization, and differentiation potential. Cytotherapy 2003; 5:362-369.
39. Erickson GR, Guilak JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic Potential of Adipose Tissue-Derived Stromal Cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 290: 763-769.
Differentiated and Native Chondrocytes in Alginate

Mardani M et al

vivo cartilage tissue engineering with 3D porous aqueous-derived silk scaffolds and mesenchymal stem cells. Biomaterials 2005; 26: 7082-7094.
41. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 1998; 238: 265-272.
42. Bernstein P, Dong M, Corbeil D, Gelinsky M, Gunter KP, Fidler S. Pellet culture elicits superior chondrogenic redifferentiation than alginate-based systems. Biotechnol Prog 2009; 25:1146-1152.
43. Mwale F, Stachura D, Roughley P, Antoniou J. Limitations of using aggrecan and type X collagen as markers of chondrogenesis in mesenchymal stem cell differentiation. J Orthop Res 2006; 24:1791-1798.
44. Sekiya I, Colter DC, Prockop DJ. BMP-6 enhances chondrogenesis in a subpopulation of human marrow stromal cells. Biochem Biophys Res Commun 2001; 284: 411-418.
45. Zhang Z, McCaffery JM, Spencer RG, Francomano CA. Hyaline cartilage engineered by chondrocytes in pellet culture: histological, immunohistochemical and ultrastructural analysis in comparison with cartilage explants. J Anat 2004; 205: 229-237.
46. Riesle J, Hollander AP, Langer R, Freed LE, Yunjko-Novakovic G. Collagen in tissue-engineered cartilage: types, structure, and crosslinks. J Cell Biochem 1998; 71: 313-327.
47. Tallheden T, Karlsson C, Brunner A, Van Der Lee J, Hagg R, Tommasini R, et al. Gene expression during redifferentiation of human articular chondrocytes. Osteoarthritis Cartilage 2004; 12: 525-535.
48. Cheng NC, Estes BT, Awad HA, Guilk F. Chondrogenic differentiation of adipose-derived adult stem cells by a porous scaffold derived from native articular cartilage extracellular matrix. Tissue Eng Part A 2009; 15: 231-241.
49. Kim HJ, ImGL. Chondrogenic differentiation of adipose tissue-derived mesenchymal stem cells: greater doses of growth factor are necessary. J Orthop Res 2009; 27:612-619.
50. Karlsson C, Brantsing C, Svensson T, Braby H, Asp J, Tallheden T, et al. Differentiation of human mesenchymal stem cells and articular chondrocytes: analysis of chondrogenic potential and expression pattern of differentiation-related transcription factors. J Orthop Res 2007; 25: 152-163.
51. Yang IH, Kim SH, Kim YH, Sun HJ, Kim SJ, Lee JW. Comparison of phenotypic characterization between “alginate bead” and “pellet” culture system as chondrogenic differentiation models for human mesenchymal stem cells. Yonsei Med J 2004; 45:891-900.
52. Park H, Temenoff JS, Tabata Y, Caplan AI, Milos AG. Injectable biodegradable hydrogel composites for rabbit marrow mesenchymal stem cell and growth factor delivery for cartilage tissue engineering. Biomaterials 2007; 28: 3217-3227.
53. Park H, Temenoff JS, Holland TA, Tabata Y, Milos AG. Delivery of TGF-Beta1 and chondrocytes via injectable, biodegradable hydrogels for cartilage tissue engineering applications. Biomaterials 2005; 26: 7095-7103.
54. Grimaud E, Heymann D, Redini F. Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Cytokine Growth Factor Rev 2002; 13:241-257.
55. Redini F, Galera P, Mauviel A, Loyau G, Pujol P. Transforming growth factor beta stimulates collagen and glycosaminoglycan biosynthesis in culture rabbit articular chondrocytes. FEBS Lett 1998; 234:172-176.
56. Skantze KA, Brinkerhoff CE, Collier JP. Use of agarose culture to measure the effect of transforming growth factor beta and epidermal growth factor on rabbit articular chondrocytes. Cancer Res 1995; 45:4416-4421.
57. Bokk JC, Beckbauer M, Domschke W, Herbst H, Pohle T. Fibrin glue, healing of gastric mucosal injury, and expression of growth factors: results from a human in vivo study. Gastrointest Endosc 2005; 61: 560-567.
58. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger ME. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998; 4:415-428.
59. Majumdar MK, Banks V, Peluso DP, Morris EA. Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J Cell Physiol 2000; 185: 98-106.
60. Zhang X, Ziran N, Goater JI, Schwarz EM, Puzas JE, Rosier RN, et al. Primary murine limb bud mesenchymal cells in long-term culture complete chondrocyte differentiation: TGF-beta delays hypertrophy and PGE2 inhibits terminal differentiation. Bone 2004; 34:809-817.
61. Williams CG, Kim TK, Taboas A, Malik A, Manson P, Ellisseff J. In vitro chondrogenesis of bone marrow-derived mesenchymal stem cells in photopolymerizing hydrogel. Tissue Eng 2003; 9:679-688.